Hetrombopag - Jiangsu Hengrui Medicine Co.
Alternative Names: Hengqu; Herombopag olamine; Hetrombopag olamine; Hytrapopapa ethanolamine; Hytrapopapamin; SHR 8735; SHR 8735 olamineLatest Information Update: 23 Aug 2024
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Developer Atridia; Jiangsu Hengrui Medicine Co.
- Class Antianaemics; Antihaemorrhagics; Aza compounds; Carboxylic acids; Furans; Pyrazolones; Small molecules; Tetrahydronaphthalenes
- Mechanism of Action Thrombopoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Aplastic anaemia; Idiopathic thrombocytopenic purpura
- Phase III Thrombocytopenia
- No development reported Unspecified
Most Recent Events
- 31 Jul 2024 Phase-III clinical trials in Thrombocytopenia in China (PO) (NCT06507436)
- 25 Jul 2024 Jiangsu Hengrui Medicine plans a phase III trial in Thrombocytopenia (PO) in July 2024 (NCT06507436)
- 09 Apr 2024 Jiangsu HengRui Medicine plans a phase I trial for Idiopathic thrombocytopenic purpura (In Volunteers) in China (PO, Tablet) in April 2024 (NCT06346925)